Literature DB >> 17621679

In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.

Xiaoying Hui1, Stephen J Baker, Ronald C Wester, Sherry Barbadillo, Anne K Cashmore, Virginia Sanders, Karin M Hold, Tsutomu Akama, Yong-Kang Zhang, Jacob J Plattner, Howard I Maibach.   

Abstract

Onychomycosis is a challenging fungal infection to treat topically, likely due to the unique properties of the nail plate. This seemingly impenetrable barrier has high resistance to the passage of antifungal drugs in sufficient concentrations to kill the causative fungi deep in the nail bed. Recently, a new class of antifungal agent was described, termed oxaboroles, which have broad-spectrum activity. These oxaboroles were designed with properties believed to be required to allow for easier transit through the nail plate. Herein, we report (i) the nail penetration results of four oxaboroles that led to the selection of AN2690, (ii) the results of the nail penetration of AN2690 from four vehicles, and (iii) the nail penetration of AN2690 in its chosen vehicle compared to a commercial control, ciclopirox. AN2690 has superior penetration compared to ciclopirox, and achieves levels within and under the nail plate that suggest it has the potential to be an effective topical treatment for onychomycosis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621679     DOI: 10.1002/jps.20901

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  17 in total

1.  In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.

Authors:  Natsuki Kubota-Ishida; Naomi Takei-Masuda; Kaori Kaneda; Yu Nagira; Tsubasa Chikada; Masahiro Nomoto; Yuji Tabata; Sho Takahata; Kazunori Maebashi; Xiaoying Hui; Howard I Maibach
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 2.  Mechanistic Insights of Formulation Approaches for the Treatment of Nail Infection: Conventional and Novel Drug Delivery Approaches.

Authors:  Agrawal Vikas; Patel Rashmin; Patel Mrunali; Rahul B Chavan; Thanki Kaushik
Journal:  AAPS PharmSciTech       Date:  2020-01-14       Impact factor: 3.246

3.  Tavaborole: first global approval.

Authors:  Anthony Markham
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

4.  In Vitro Resistance and Evolution of Resistance to Tavaborole in Trichophyton rubrum.

Authors:  Diletta Mazzantini; Francesco Celandroni; Marco Calvigioni; Antonella Lupetti; Emilia Ghelardi
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  Synthesis of a boron-containing amidoxime reagent and its application to synthesize functionalized oxadiazole and quinazolinone derivatives.

Authors:  Bhaskar C Das; Nitesh K Nandwana; Devi P Ojha; Sasmita Das; Todd Evans
Journal:  Tetrahedron Lett       Date:  2022-01-25       Impact factor: 2.032

6.  Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections.

Authors:  Nathan Stasko; Kimberly McHale; Stanley J Hollenbach; Megan Martin; Ryan Doxey
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  Iontophoretically enhanced ciclopirox delivery into and across human nail plate.

Authors:  Jinsong Hao; Kelly A Smith; S Kevin Li
Journal:  J Pharm Sci       Date:  2009-10       Impact factor: 3.534

Review 8.  Iontophoresis to Overcome the Challenge of Nail Permeation: Considerations and Optimizations for Successful Ungual Drug Delivery.

Authors:  Kevin Chen; Vinam Puri; Bozena Michniak-Kohn
Journal:  AAPS J       Date:  2021-01-13       Impact factor: 4.009

9.  5-Fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol.

Authors:  Izabela D Madura; Agnieszka Adamczyk-Woźniak; Michał Jakubczyk; Andrzej Sporzyński
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-01-15

Review 10.  tRNAs as antibiotic targets.

Authors:  Shaileja Chopra; John Reader
Journal:  Int J Mol Sci       Date:  2014-12-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.